title: Osmolality of antisense oligonucleotide parenteral formulations: Implications on counterion dissociation and recommended osmometry techniques.
abstract: The intrinsic osmolality of aqueous solutions of sodium salt antisense oligonucleotides (ASOs) has been studied to inform formulation practices, understand the molecular basis underlying the difference between theoretical and empirical results, and determine suitable measurement methods. It was found that regardless of nucleotide sequence, ASO concentration of ∼140mg/mL has isotonic osmolality of ∼290mOsm/kg water (SI unit: mmol osmotically-active particles/kg water), such that lower concentration formulations require excipients for tonicity adjustment. The range of osmolality values at a given active ingredient concentration can be ascribed to drug substance lot-to-lot purity differences impacting total oligonucleotide content (i.e., including oligonucleotide-related impurities). Empirical osmolality measurements were found to be ∼70% of theoretical values, which corresponds to an osmotic coefficient value of ∼0.7, thus inferring incomplete counterion dissociation. When comparing theoretical (ideal) osmolality of multiple sequences with various nucleotide compositions and chemistries at the same w/v concentration, the "average osmolar mass" (molar mass of the oligonucleotide, including the sodium counterions, divided by the ideal Van't Hoff factor, iid) appears to be the strongest factor governing theoretical osmolality values. Other factors examined were the sequence length, backbone chemistry, 2' sugar chemistry, and nucleotide composition. A head-to-head comparison between two osmolality techniques showed that vapor pressure osmometry is generally more suitable than freezing point osmometry for oligonucleotide solutions greater than ∼150mg/mL due to viscosity effects, but the two techniques are comparable otherwise.
authors.affiliation: Ionis Pharmaceuticals, Inc., Pharmaceutical Development, 2855 Gazelle Ct., Carlsbad, CA 92010, United States.
authors.forename: Marc
authors.initials: M
authors.lastname: Lim
authors.affiliation: Ionis Pharmaceuticals, Inc., Pharmaceutical Development, 2855 Gazelle Ct., Carlsbad, CA 92010, United States. Electronic address: adibble@ionisph.com.
authors.forename: Andrew
authors.initials: A
authors.lastname: Dibble
mesh_terms: D004339:Drug Compounding; D007263:Infusions, Parenteral; D020319:Oligodeoxyribonucleotides, Antisense / Q000737:chemistry*; D009994:Osmolar Concentration
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense
keywords: Antisense oligonucleotide; Counterion dissociation; Osmolality; Osmometry